Literature DB >> 30262586

Walker BA, Mavrommatis K, Wardell CP, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132(6):587-597.

.   

Abstract

Entities:  

Year:  2018        PMID： 30262586      PMCID： PMC6161766          DOI： 10.1182/blood-2018-08-870022

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

1.  Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.

Authors:  Deepak Perumal; Naoko Imai; Alessandro Laganà; John Finnigan; David Melnekoff; Violetta V Leshchenko; Alexander Solovyov; Deepu Madduri; Ajai Chari; Hearn Jay Cho; Joel T Dudley; Joshua D Brody; Sundar Jagannath; Benjamin Greenbaum; Sacha Gnjatic; Nina Bhardwaj; Samir Parekh
Journal:  Clin Cancer Res       Date:  2019-12-19       Impact factor: 12.531

2.  Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.

Authors:  Stephan R Bohl; Laura K Schmalbrock; Imke Bauhuf; Tatjana Meyer; Anna Dolnik; Martin Szyska; Tamara J Blätte; Sarah Knödler; Linda Röhner; Denise Miller; Miriam Kull; Christian Langer; Hartmut Döhner; Anthony Letai; Frederik Damm; Dirk Heckl; Lars Bullinger; Jan Krönke
Journal:  Blood Adv       Date:  2021-05-11

3.  IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM.

Authors:  Abdul Hamid Bazarbachi; Hervé Avet-Loiseau; Raphael Szalat; Anil Aktas Samur; Zachary Hunter; Masood Shammas; Jill Corre; Mariateresa Fulciniti; Kenneth C Anderson; Giovanni Parmigiani; Steven P Treon; Mohamad Mohty; Nikhil C Munshi; Mehmet Kemal Samur
Journal:  Blood       Date:  2021-11-18       Impact factor: 22.113

4.  Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death.

Authors:  Debora Soncini; Paola Minetto; Claudia Martinuzzi; Pamela Becherini; Valeria Fenu; Fabio Guolo; Katia Todoerti; Giovanni Calice; Paola Contini; Maurizio Miglino; Giulia Rivoli; Sara Aquino; Alida Dominietto; Antonia Cagnetta; Mario Passalacqua; Santina Bruzzone; Alessio Nencioni; Massimo Zucchetti; Tommaso Ceruti; Antonino Neri; Roberto M Lemoli; Michele Cea
Journal:  Blood Adv       Date:  2020-09-22

5.  TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC.

Authors:  Stacy Grieve; Gabriel Wajnberg; Miranda Lees; Simi Chacko; Jackson Weir; Nicolas Crapoulet; Tony Reiman
Journal:  Blood Adv       Date:  2019-11-26

6.  Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent.

Authors:  Alberto Risueño; Patrick R Hagner; Fadi Towfic; Celia Fontanillo; Amira Djebbari; Joel S Parker; Clifton P Drew; Grzegorz S Nowakowski; Matthew J Maurer; James R Cerhan; Xin Wei; Yan Ren; Chung-Wein Lee; Suzana Couto; Maria Wang; Michael Pourdehnad; Anita K Gandhi; Matthew W B Trotter
Journal:  Blood       Date:  2020-03-26       Impact factor: 22.113

7.  Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.

Authors:  Sarah Gooding; Naser Ansari-Pour; Fadi Towfic; María Ortiz Estévez; Philip P Chamberlain; Kao-Tai Tsai; Erin Flynt; Marissa Hirst; Dan Rozelle; Paula Dhiman; Paola Neri; Karthik Ramasamy; Nizar Bahlis; Paresh Vyas; Anjan Thakurta
Journal:  Blood       Date:  2021-01-14       Impact factor: 25.476

8.  Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group.

Authors:  Mehmet Kemal Samur; Anil Aktas Samur; Mariateresa Fulciniti; Raphael Szalat; Tessa Han; Masood Shammas; Paul Richardson; Florence Magrangeas; Stephane Minvielle; Jill Corre; Philippe Moreau; Anjan Thakurta; Kenneth C Anderson; Giovanni Parmigiani; Hervé Avet-Loiseau; Nikhil C Munshi
Journal:  J Clin Oncol       Date:  2020-07-20       Impact factor: 44.544

9.  Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma.

Authors:  Aneta Mikulasova; Cody Ashby; Ruslana G Tytarenko; Pingping Qu; Adam Rosenthal; Judith A Dent; Katie R Ryan; Michael A Bauer; Christopher P Wardell; Antje Hoering; Konstantinos Mavrommatis; Matthew Trotter; Shayu Deshpande; Shmuel Yaccoby; Erming Tian; Jonathan Keats; Daniel Auclair; Graham H Jackson; Faith E Davies; Anjan Thakurta; Gareth J Morgan; Brian A Walker
Journal:  Haematologica       Date:  2019-06-20       Impact factor: 9.941

10.  Prognostic value of integrated cytogenetic, somatic variation, and copy number variation analyses in Korean patients with newly diagnosed multiple myeloma.

Authors:  Nuri Lee; Sung-Min Kim; Youngeun Lee; Dajeong Jeong; Jiwon Yun; Sohee Ryu; Sung-Soo Yoon; Yong-Oon Ahn; Sang Mee Hwang; Dong Soon Lee
Journal:  PLoS One       Date:  2021-02-05       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.